Posted by Michael Wonder on 02 Oct 2024
Sagimet receives FDA breakthrough therapy designation for denifanstat in MASH
1 October 2024 - Supported by positive data from Phase 2b FASCINATE-2 trial of denifanstat in patients with MASH.
Sagimet Biosciences today announced that the US FDA granted breakthrough therapy designation to denifanstat for treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
